The immunosuppressive drug, rapamycin, interferes with an undefined signaling pathway required for the progression of G-phase T-cells into S phase. Genetic analyses in yeast indicate that binding of rapamycin to its intracellular receptor, FKBP12, generates a toxic complex that inhibits cell growth in G phase. These analyses implicated two related proteins, TOR1 and TOR2, as targets of the FKBP12-rapamycin complex in yeast. In this study, we have used a glutathione S-transferase (GST)-FKBP12-rapamycin affinity matrix to isolate putative mammalian targets of rapamycin (mTOR) from tissue extracts. In the presence of rapamycin, immobilized GST-FKBP12 specifically precipitates similar high molecular mass proteins from both rat brain and murine T-lymphoma cell extracts. Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines. The latter results suggest that mTOR is a relevant target of rapamycin in these cells. Finally, we report the isolation of a full-length mTOR cDNA that encodes a direct ligand for the FKBP12-rapamycin complex. The deduced amino acid sequence of mTOR displays 42 and 45% identity to those of yeast TOR1 and TOR2, respectively. These results strongly suggest that the FKBP12-rapamycin complex interacts with homologous ligands in yeast and mammalian cells and that the loss of mTOR function is directly related to the inhibitory effect of rapamycin on G- to S-phase progression in T-lymphocytes and other sensitive cell types.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. H. Squarize, R. M. Castilho, and J. S. Gutkind Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin Cancer Res., September 1, 2008; 68(17): 7066 - 7072. [Abstract] [Full Text] [PDF]

				B. Boland, A. Kumar, S. Lee, F. M. Platt, J. Wegiel, W. H. Yu, and R. A. Nixon Autophagy Induction and Autophagosome Clearance in Neurons: Relationship to Autophagic Pathology in Alzheimer's Disease J. Neurosci., July 2, 2008; 28(27): 6926 - 6937. [Abstract] [Full Text] [PDF]

				L. Wang, T. E. Harris, and J. C. Lawrence Jr. Regulation of Proline-rich Akt Substrate of 40 kDa (PRAS40) Function by Mammalian Target of Rapamycin Complex 1 (mTORC1)-mediated Phosphorylation J. Biol. Chem., June 6, 2008; 283(23): 15619 - 15627. [Abstract] [Full Text] [PDF]

				C. Gridelli, P. Maione, and A. Rossi The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer Oncologist, February 1, 2008; 13(2): 139 - 147. [Abstract] [Full Text] [PDF]

				L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]

				X. Wan and L. J. Helman The Biology Behind mTOR Inhibition in Sarcoma Oncologist, August 1, 2007; 12(8): 1007 - 1018. [Abstract] [Full Text] [PDF]

				C. Cerboni, A. Zingoni, M. Cippitelli, M. Piccoli, L. Frati, and A. Santoni Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis Blood, July 15, 2007; 110(2): 606 - 615. [Abstract] [Full Text] [PDF]

				L. Wang, T. E. Harris, R. A. Roth, and J. C. Lawrence Jr PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding J. Biol. Chem., July 6, 2007; 282(27): 20036 - 20044. [Abstract] [Full Text] [PDF]

				B. C. Fuchs, R. E. Finger, M. C. Onan, and B. P. Bode ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells Am J Physiol Cell Physiol, July 1, 2007; 293(1): C55 - C63. [Abstract] [Full Text] [PDF]

				R. T. Abraham and J. J. Gibbons The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy Clin. Cancer Res., June 1, 2007; 13(11): 3109 - 3114. [Abstract] [Full Text] [PDF]

				L. Wang, C. J. Rhodes, and J. C. Lawrence Jr. Activation of Mammalian Target of Rapamycin (mTOR) by Insulin Is Associated with Stimulation of 4EBP1 Binding to Dimeric mTOR Complex 1 J. Biol. Chem., August 25, 2006; 281(34): 24293 - 24303. [Abstract] [Full Text] [PDF]

				J. Klekota, F. P. Roth, and S. L. Schreiber Query Chem: a Google-powered web search combining text and chemical structures Bioinformatics, July 1, 2006; 22(13): 1670 - 1673. [Abstract] [Full Text] [PDF]

				D. Cota, K. Proulx, K. A. B. Smith, S. C. Kozma, G. Thomas, S. C. Woods, and R. J. Seeley Hypothalamic mTOR signaling regulates food intake. Science, May 12, 2006; 312(5775): 927 - 930. [Abstract] [Full Text] [PDF]

				J. M. Albert, K. W. Kim, C. Cao, and B. Lu Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer Mol. Cancer Ther., May 1, 2006; 5(5): 1183 - 1189. [Abstract] [Full Text] [PDF]

				J. M. Shillingford, N. S. Murcia, C. H. Larson, S. H. Low, R. Hedgepeth, N. Brown, C. A. Flask, A. C. Novick, D. A. Goldfarb, A. Kramer-Zucker, et al. From the Cover: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease PNAS, April 4, 2006; 103(14): 5466 - 5471. [Abstract] [Full Text] [PDF]

				Q. Xu, J. E. Thompson, and M. Carroll mTOR regulates cell survival after etoposide treatment in primary AML cells Blood, December 15, 2005; 106(13): 4261 - 4268. [Abstract] [Full Text] [PDF]

				D. D. Sarbassov and D. M. Sabatini Redox Regulation of the Nutrient-sensitive Raptor-mTOR Pathway and Complex J. Biol. Chem., November 25, 2005; 280(47): 39505 - 39509. [Abstract] [Full Text] [PDF]

				P. Amornphimoltham, V. Patel, A. Sodhi, N. G. Nikitakis, J. J. Sauk, E. A. Sausville, A. A. Molinolo, and J. S. Gutkind Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck Cancer Res., November 1, 2005; 65(21): 9953 - 9961. [Abstract] [Full Text] [PDF]

				J. E. Foley, U. Jung, A. Miera, T. Borenstein, J. Mariotti, M. Eckhaus, B. E. Bierer, and D. H. Fowler Ex Vivo Rapamycin Generates Donor Th2 Cells That Potently Inhibit Graft-versus-Host Disease and Graft-versus-Tumor Effects via an IL-4-Dependent Mechanism J. Immunol., November 1, 2005; 175(9): 5732 - 5743. [Abstract] [Full Text] [PDF]

				B. Adams, A. Musiyenko, R. Kumar, and S. Barik A Novel Class of Dual-family Immunophilins J. Biol. Chem., July 1, 2005; 280(26): 24308 - 24314. [Abstract] [Full Text] [PDF]

				M. Minhajuddin, F. Fazal, K. M. Bijli, Md. R. Amin, and A. Rahman Inhibition of Mammalian Target of Rapamycin Potentiates Thrombin-Induced Intercellular Adhesion Molecule-1 Expression by Accelerating and Stabilizing NF-{kappa}B Activation in Endothelial Cells J. Immunol., May 1, 2005; 174(9): 5823 - 5829. [Abstract] [Full Text] [PDF]

				R. E. Brown Morphoproteomic Analysis of Osteolytic Langerhans Cell Histiocytosis with Therapeutic Implications Ann. Clin. Lab. Sci., April 1, 2005; 35(2): 131 - 136. [Abstract] [Full Text] [PDF]

				S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Onc., April 1, 2005; 16(4): 525 - 537. [Abstract] [Full Text] [PDF]

				M. Hahn, W. Li, C. Yu, M. Rahmani, P. Dent, and S. Grant Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways Mol. Cancer Ther., March 1, 2005; 4(3): 457 - 470. [Abstract] [Full Text] [PDF]

				Y. S. Kwon, H. S. Hong, J. C. Kim, J. S. Shin, and Y. Son Inhibitory Effect of Rapamycin on Corneal Neovascularization In Vitro and In Vivo Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 454 - 460. [Abstract] [Full Text] [PDF]

				L. P. McMahon, W. Yue, R. J. Santen, and J. C. Lawrence Jr Farnesylthiosalicylic Acid Inhibits Mammalian Target of Rapamycin (mTOR) Activity Both in Cells and in Vitro by Promoting Dissociation of the mTOR-Raptor Complex Mol. Endocrinol., January 1, 2005; 19(1): 175 - 183. [Abstract] [Full Text] [PDF]

				I. Mothe-Satney, N. Gautier, C. Hinault, J. C. Lawrence Jr., and E. Van Obberghen In Rat Hepatocytes Glucagon Increases Mammalian Target of Rapamycin Phosphorylation on Serine 2448 but Antagonizes the Phosphorylation of Its Downstream Targets Induced by Insulin and Amino Acids J. Biol. Chem., October 8, 2004; 279(41): 42628 - 42637. [Abstract] [Full Text] [PDF]

				N. Hay and N. Sonenberg Upstream and downstream of mTOR Genes & Dev., August 15, 2004; 18(16): 1926 - 1945. [Abstract] [Full Text] [PDF]

				M. Murakami, T. Ichisaka, M. Maeda, N. Oshiro, K. Hara, F. Edenhofer, H. Kiyama, K. Yonezawa, and S. Yamanaka mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells Mol. Cell. Biol., August 1, 2004; 24(15): 6710 - 6718. [Abstract] [Full Text] [PDF]

				L. Hou and E. Klann Activation of the Phosphoinositide 3-Kinase-Akt-Mammalian Target of Rapamycin Signaling Pathway Is Required for Metabotropic Glutamate Receptor-Dependent Long-Term Depression J. Neurosci., July 14, 2004; 24(28): 6352 - 6361. [Abstract] [Full Text] [PDF]

				M. E. Hartman, J. C. O'Connor, J. P. Godbout, K. D. Minor, V. R. Mazzocco, and G. G. Freund Insulin Receptor Substrate-2-dependent Interleukin-4 Signaling in Macrophages Is Impaired in Two Models of Type 2 Diabetes Mellitus J. Biol. Chem., July 2, 2004; 279(27): 28045 - 28050. [Abstract] [Full Text] [PDF]

				E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman, J. Boni, C. Leister, J. Korth-Bradley, A. Hanauske, and J.-P. Armand Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer J. Clin. Oncol., June 15, 2004; 22(12): 2336 - 2347. [Abstract] [Full Text] [PDF]

				S. W. Y. Cheng, L. G. D. Fryer, D. Carling, and P. R. Shepherd Thr2446 Is a Novel Mammalian Target of Rapamycin (mTOR) Phosphorylation Site Regulated by Nutrient Status J. Biol. Chem., April 16, 2004; 279(16): 15719 - 15722. [Abstract] [Full Text] [PDF]

				T. Stromberg, A. Dimberg, A. Hammarberg, K. Carlson, A. Osterborg, K. Nilsson, and H. Jernberg-Wiklund Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone Blood, April 15, 2004; 103(8): 3138 - 3147. [Abstract] [Full Text] [PDF]

				Z. He, L. Li, and S. Luan Immunophilins and Parvulins. Superfamily of Peptidyl Prolyl Isomerases in Arabidopsis Plant Physiology, April 1, 2004; 134(4): 1248 - 1267. [Abstract] [Full Text] [PDF]

				T. E. Harris and J. C. Lawrence Jr. TOR Signaling Sci. Signal., December 9, 2003; 2003(212): re15 - re15. [Abstract] [Full Text] [PDF]

				A. L. Edinger, C. M. Linardic, G. G. Chiang, C. B. Thompson, and R. T. Abraham Differential Effects of Rapamycin on Mammalian Target of Rapamycin Signaling Functions in Mammalian Cells Cancer Res., December 1, 2003; 63(23): 8451 - 8460. [Abstract] [Full Text] [PDF]

				A. G. Bader, K. A. Felts, N. Jiang, H. W. Chang, and P. K. Vogt Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway PNAS, October 14, 2003; 100(21): 12384 - 12389. [Abstract] [Full Text] [PDF]

				K. Song, S. C. Cornelius, M. Reiss, and D. Danielpour Insulin-like Growth Factor-I Inhibits Transcriptional Responses of Transforming Growth Factor-{beta} by Phosphatidylinositol 3-Kinase/Akt-dependent Suppression of the Activation of Smad3 but Not Smad2 J. Biol. Chem., October 3, 2003; 278(40): 38342 - 38351. [Abstract] [Full Text] [PDF]

				J. M. Peralba, L. deGraffenried, W. Friedrichs, L. Fulcher, V. Grunwald, G. Weiss, and M. Hidalgo Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients Clin. Cancer Res., August 1, 2003; 9(8): 2887 - 2892. [Abstract] [Full Text] [PDF]

				K. M. Choi, L. P. McMahon, and J. C. Lawrence Jr. Two Motifs in the Translational Repressor PHAS-I Required for Efficient Phosphorylation by Mammalian Target of Rapamycin and for Recognition by Raptor J. Biol. Chem., May 23, 2003; 278(22): 19667 - 19673. [Abstract] [Full Text] [PDF]

				A. M. Woltman and C. van Kooten Functional modulation of dendritic cells to suppress adaptive immune responses J. Leukoc. Biol., April 1, 2003; 73(4): 428 - 441. [Abstract] [Full Text] [PDF]

				U. Krummrei, E.-E. Baulieu, and B. Chambraud The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis PNAS, March 4, 2003; 100(5): 2444 - 2449. [Abstract] [Full Text] [PDF]

				A. M. Woltman, S. W. van der Kooij, P. J. Coffer, R. Offringa, M. R. Daha, and C. van Kooten Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression Blood, February 15, 2003; 101(4): 1439 - 1445. [Abstract] [Full Text] [PDF]

				C. R. Sinars, J. Cheung-Flynn, R. A. Rimerman, J. G. Scammell, D. F. Smith, and J. Clardy Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes PNAS, February 4, 2003; 100(3): 868 - 873. [Abstract] [Full Text] [PDF]

				J. L. Crespo and M. N. Hall Elucidating TOR Signaling and Rapamycin Action: Lessons from Saccharomyces cerevisiae Microbiol. Mol. Biol. Rev., December 1, 2002; 66(4): 579 - 591. [Abstract] [Full Text] [PDF]

				L. P. McMahon, K. M. Choi, T.-A. Lin, R. T. Abraham, and J. C. Lawrence Jr. The Rapamycin-Binding Domain Governs Substrate Selectivity by the Mammalian Target of Rapamycin Mol. Cell. Biol., November 1, 2002; 22(21): 7428 - 7438. [Abstract] [Full Text] [PDF]

				T. Peng, T. R. Golub, and D. M. Sabatini The Immunosuppressant Rapamycin Mimics a Starvation-Like Signal Distinct from Amino Acid and Glucose Deprivation Mol. Cell. Biol., August 1, 2002; 22(15): 5575 - 5584. [Abstract] [Full Text] [PDF]

				X. Zhang, L. Shu, H. Hosoi, K. G. Murti, and P. J. Houghton Predominant Nuclear Localization of Mammalian Target of Rapamycin in Normal and Malignant Cells in Culture J. Biol. Chem., July 26, 2002; 277(31): 28127 - 28134. [Abstract] [Full Text] [PDF]

				D. C. Fingar, S. Salama, C. Tsou, E. Harlow, and J. Blenis Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E Genes & Dev., June 15, 2002; 16(12): 1472 - 1487. [Abstract] [Full Text] [PDF]

				P. Ghosh, M. A. Buchholz, S. Yano, D. Taub, and D. L. Longo Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway Blood, May 29, 2002; 99(12): 4517 - 4524. [Abstract] [Full Text] [PDF]

				T. H. Reynolds IV, S. C. Bodine, and J. C. Lawrence Jr. Control of Ser2448 Phosphorylation in the Mammalian Target of Rapamycin by Insulin and Skeletal Muscle Load J. Biol. Chem., May 10, 2002; 277(20): 17657 - 17662. [Abstract] [Full Text] [PDF]

				M. B. Dilling, G. S. Germain, L. Dudkin, A. L. Jayaraman, X. Zhang, F. C. Harwood, and P. J. Houghton 4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin J. Biol. Chem., April 12, 2002; 277(16): 13907 - 13917. [Abstract] [Full Text] [PDF]

				M. J. Jang, M. Jwa, J.-H. Kim, and K. Song Selective Inhibition of MAPKK Wis1 in the Stress-activated MAPK Cascade of Schizosaccharomyces pombe by Novel Berberine Derivatives J. Biol. Chem., March 29, 2002; 277(14): 12388 - 12395. [Abstract] [Full Text] [PDF]

				D. J. Kwiatkowski, H. Zhang, J. L. Bandura, K. M. Heiberger, M. Glogauer, N. el-Hashemite, and H. Onda A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells Hum. Mol. Genet., March 1, 2002; 11(5): 525 - 534. [Abstract] [Full Text] [PDF]

H. Fukazawa, K. Noguchi, Y. Murakami, and Y. Uehara Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated Extracellular- regulated Kinase (ERK) Pathway Mol. Cancer Ther., March 1, 2002; 1(5): 303 - 309. [Abstract]